KBC Group NV Sells 2,974 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

KBC Group NV trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 34.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,661 shares of the biotechnology company’s stock after selling 2,974 shares during the period. KBC Group NV’s holdings in BioCryst Pharmaceuticals were worth $43,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. CWM LLC increased its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC increased its position in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth $63,000. Finally, Natixis grew its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 9,350 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.60 on Friday. The stock has a market capitalization of $1.57 billion, a PE ratio of -12.46 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The business’s fifty day moving average price is $7.66 and its 200-day moving average price is $7.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BCRX has been the subject of several recent research reports. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.